TC
BMY.RT

Truvestments Capital’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Truvestments Capital’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-75
Closed – – 614
2020
Q2 		$0 Sell
75
-335
-82% -$1.21K ﹤0.01% 641
2020
Q1 		$1K Buy
+410
New +$1.35K ﹤0.01% 501

Other funds holding BMY.RT

LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Truvestments Capital's BMY.RT Position: Q3 2020 in Review

Truvestments Capital sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q3 2020, closing a stake of 75 shares.

Truvestments Capital first reported a position in BMY.RT in Q1 2020 and held it in 2 quarters. The position peaked at $1K in Q1 2020. 571 funds tracked by Wall St. Rank hold BMY.RT as of Q3 2020.

  • Truvestments Capital reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q3 2020 after selling out during the quarter.
  • Truvestments Capital sold 75 Bristol-Myers Squibb Company Contingent Value Rights shares in Q3 2020.
  • Truvestments Capital first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 2 quarters.
  • Truvestments Capital's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1K in Q1 2020.
  • 571 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q3 2020.

Based on Truvestments Capital's 13F filing for Q3 2020, filed 13 Nov 2020.